BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Bioventus Inc.

Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026

$13.49+0.19 (+1.43%)

Close on Oct 19, 2026

Market cap: $955.61M
P/E (TTM): 17.5
Dividend yield: –

Bioventus Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Revenue	568	573	512	512	431	321	340
Cost of Revenue	180	185	184	181	128	88	91
Gross Profit	388	388	328	331	303	234	249
Research & Development	12	14	13	24	19	11	11
Selling, General & Admin	314	344	304	332	254	193	198
Advertising Expenses	4.14	4.42	3.85	5.20	3.87	2.77	2.35
Operating Income	54	-15	-82	-167	12	21	31
Other Non-Operating Income	-28	-37	-39	-22	-2.57	-5.32	-22
Merger & Restructuring Charges	2.24	-0.05	0.84	6.78	2.49	0.56	0.58
Asset Impairment Charges	0	36	79	135	7.04	0	0
Gain (Loss) on Sale of Assets	-0.08	-0.29	-2.04	0	0	–	–
Legal Settlements	–	–	–	–	–	-3.60	–
Pretax Income	26	-52	-121	-189	9.49	16	9.69
Income Tax Expense	-1.57	-5.29	0.09	-44	-1.97	1.19	1.58
Income from Continuing Operations	23	-36	-97	-104	11	15	8.11
Income from Discontinued Operations	0	0	-74	-69	-1.87	0	-1.82
Net Income incl. Noncontrolling Interests	27	-47	-196	-213	9.59	15	6.30
Minority Interest in Earnings	–	-11	–	-55	-9.79	-1.69	-0.55
Net Income	23	-36	-156	-159	19	16	6.85
Net Income to Common	–	–	–	-159	–	–	–
EPS (Basic)(per share)	0.34	-0.56	-2.49	-2.59	-0.15	–	–
EPS (Diluted)(per share)	0.33	-0.56	-2.49	-2.59	-0.15	–	–
Shares Outstanding (Basic, Weighted)(shares)	67	65	63	61	45	–	–
Shares Outstanding (Diluted, Weighted)(shares)	69	65	63	61	45	–	–
EBITDA	101	34	-24	-112	47	50	62

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 27, 2026

Profitability, TTM

Gross margin: 68.7%
Operating margin: 10.0%
Net margin: 9.4%
Return on equity, FY2025: 13.7%

Financial strength

Current ratio: 1.69
Debt to equity: 1.09
Debt to assets: 36.9%
Cash to current liabilities: 19.3%

Valuation

P/E ratio: 17.5
Price to sales: 1.64
Price to book: 4.19
Dividend yield: –